logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9493451 B1

PDFFull Text
Date of Patent:
Nov. 15, 2016

Filed:

May. 16, 2012

Amine derivatives as potassium channel blockers

Applicants:

Andrew Harvey, Goodwood, AU;

Agnes Bombrun, Chambesy, CH;

Rachel Cooke, Woodville West, AU;

Isabelle Jeanclaude-etter, Bellevue, CH;

Nathan Kuchel, Cumberland Park, AU;

Jerome Molette, Versonnex, FR;

Jorgen Mould, Semaphore South, AU;

Dharam Paul, Flinders Park, AU;

Rajinder Singh, Cowandilla, AU;

Cristina Donini, Geneva, CH;

Veronique Colovray, Geneva, CH;

Thomas Avery, Rostrevor, AU;

Julia Crossman, Thebarton, AU;

Justin Ripper, Cumberland Park, AU;

Inventors:

Andrew Harvey, Goodwood, AU;

Agnes Bombrun, Chambesy, CH;

Rachel Cooke, Woodville West, AU;

Isabelle Jeanclaude-Etter, Bellevue, CH;

Nathan Kuchel, Cumberland Park, AU;

Jerome Molette, Versonnex, FR;

Jorgen Mould, Semaphore South, AU;

Dharam Paul, Flinders Park, AU;

Rajinder Singh, Cowandilla, AU;

Cristina Donini, Geneva, CH;

Veronique Colovray, Geneva, CH;

Thomas Avery, Rostrevor, AU;

Julia Crossman, Thebarton, AU;

Justin Ripper, Cumberland Park, AU;

Assignees:

Bionomics Limited, Thebarton, AU;

Merck Patent GmbH, Darmstadt, DE;

Attorneys:

Choate, Hall & Stewart LLP

Charles E. Lyon

Primary Examiner:

Nizal Chandrakumar

Int. Cl.
CPC ...
A61K 31/497 (2006.01); C07D 451/04 (2006.01); C07D 309/14 (2006.01); C07D 213/89 (2006.01); C07D 231/12 (2006.01); C07D 233/56 (2006.01); C07D 401/12 (2006.01); C07D 237/08 (2006.01); C07D 239/24 (2006.01); C07D 405/12 (2006.01); C07D 411/12 (2006.01); C07C 217/90 (2006.01); C07D 413/12 (2006.01); C07D 241/12 (2006.01); C07D 209/52 (2006.01); C07D 211/16 (2006.01); C07D 211/26 (2006.01); C07D 211/38 (2006.01); C07D 213/16 (2006.01); C07D 213/61 (2006.01); C07D 213/64 (2006.01); C07D 213/70 (2006.01); C07D 213/40 (2006.01); C07D 241/18 (2006.01);
U.S. Cl.
CPC ...
C07D 451/04 (2013.01); C07C 217/90 (2013.01); C07D 209/52 (2013.01); C07D 211/16 (2013.01); C07D 211/26 (2013.01); C07D 211/38 (2013.01); C07D 213/16 (2013.01); C07D 213/40 (2013.01); C07D 213/61 (2013.01); C07D 213/64 (2013.01); C07D 213/70 (2013.01); C07D 213/89 (2013.01); C07D 231/12 (2013.01); C07D 233/56 (2013.01); C07D 237/08 (2013.01); C07D 239/24 (2013.01); C07D 241/12 (2013.01); C07D 241/18 (2013.01); C07D 309/14 (2013.01); C07D 401/12 (2013.01); C07D 405/12 (2013.01); C07D 411/12 (2013.01); C07D 413/12 (2013.01);
Abstract

The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.

Find Patent Forward Citations

Loading…